Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), a $16.28 billion market cap company with impressive 89% gross margins, has sold shares worth approximately $3.65 million, according to a recent SEC filing. The transactions occurred on January 13, 2025, with shares sold at prices ranging from $360.85 to $367.99. These sales were part of a pre-arranged trading plan under Rule 10b5-1. Prior to the sales, Benkowitz exercised stock options to acquire 10,000 shares at $111 each. The stock, trading at a P/E of 15x, is currently valued near its InvestingPro Fair Value, with 12 additional exclusive ProTips available for subscribers analyzing the company's strong financial health rating of "Excellent."
In other recent news, United Therapeutics Corporation reported a significant increase in its third-quarter revenue for 2024, reaching $749 million, driven by the strong performance of key products such as Tyvaso. The company also completed a $1 billion accelerated share repurchase program. Analysts at H.C. Wainwright reaffirmed a Buy rating on the company, citing strategic positioning and proactive measures such as initiating contracts with Part D payers. Ladenburg Thalmann maintained a Neutral rating but raised the price target to $344 from the previous $319.
Furthermore, United Therapeutics Corporation announced the successful transplantation of a gene-edited pig kidney, UKidney, into a human patient. The company is preparing an investigational new drug application (IND) for the UKidney, with plans to initiate a human clinical study in 2025, pending FDA clearance.
TD Cowen outlined ten anticipated catalysts for the year 2025, including clinical trial data releases and regulatory milestones. Notably, ANAB is expected to release Phase II rheumatoid arthritis data for Rosnilimab and UTHR is looking to extend the success of its Tyvaso treatment to a Phase III idiopathic pulmonary fibrosis program.
These are among the recent developments in the biotech sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.